Us Respiratory Virus Vaccines Market Size By Applications, By Type, By End-User, By Deployment & By Technology 2032
Respiratory Virus Vaccines Market was valued at USD 5.1 Billion in 2022 and is projected to reach USD 11.9 Billion by 2030, growing at a CAGR of 11.1% from 2024 to 2030.
The U.S. respiratory virus vaccines market is undergoing significant transformations, influenced by recent regulatory decisions, market dynamics, and emerging health concerns. In 2024, the market was valued at approximately USD 94.60 billion and is projected to reach USD 101.56 billion by 2030, growing at a compound annual growth rate (CAGR) of 1.15%.
One notable development is the decline in sales of Respiratory Syncytial Virus (RSV) vaccines from major pharmaceutical companies such as GSK and Pfizer. This downturn follows regulatory adjustments that narrowed the recommended age group for RSV vaccinations and designated the vaccine as a once-in-a-lifetime shot, excluding individuals who received it the previous year. Independent pharmacists have reported a reduction in demand by up to two-thirds compared to the prior year. This shift has significant implications, considering that vaccines constitute over one-fifth of Pfizer's sales.
In parallel, the U.S. government is intensifying efforts to combat avian influenza. The Department of Agriculture has announced plans to allocate up to $1 billion to address the ongoing bird flu outbreak, which has led to substantial poultry losses since 2022. This funding aims to support various measures, including free biosecurity audits for farms and increased compensation rates for farmers required to cull infected flocks. Additionally, the administration is boosting egg imports to mitigate soaring prices caused by the outbreak.
Despite these challenges, the overall U.S. vaccines market demonstrates resilience. In 2022, the market was valued at USD 34.37 billion and is projected to grow at a CAGR of 8.2% during the forecast period. This growth is driven by factors such as the rising incidence of infectious diseases, increased public awareness regarding immunization, and substantial investments in vaccine research and development by both governmental and non-governmental organizations.
However, the market faces hurdles, including vaccine hesitancy and stringent regulatory requirements. Public skepticism, fueled by misinformation and concerns about vaccine safety, poses a significant challenge to achieving widespread immunization coverage. Moreover, the complex and time-consuming processes involved in vaccine development, testing, and approval can delay the availability of new vaccines, impacting market growth.
In summary, the U.S. respiratory virus vaccines market is navigating a complex landscape marked by regulatory changes, emerging health threats, and evolving public perceptions. While challenges persist, ongoing investments in research and proactive public health initiatives are poised to drive the market forward, ensuring preparedness against current and future respiratory health challenges.
Get an In-Depth Research Analysis of the Global Respiratory Virus Vaccines Market Size And Forecast [2025-2032]
CSL Limited
Sanofi
AstraZeneca
Merck & Co.
Inc.
GlaxoSmithKline plc
Serum Institute of India Pvt. Ltd.
Bharat Biotech
Sinovac Biotech Ltd.
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Respiratory Virus Vaccines Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Respiratory Virus Vaccines Market
Inactivated Vaccines
Live Attenuated Vaccines
Subunit Vaccines
mRNA Vaccines
DNA Vaccines
Influenza Vaccines
RSV (Respiratory Syncytial Virus) Vaccines
Corona Virus Vaccines
Parainfluenza Virus Vaccines
Adenovirus Vaccines
Intramuscular Vaccines
Intranasal Vaccines
Subcutaneous Vaccines
Pediatrics
Adults
Elderly
Immunocompromised Individuals
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Government Health Programs
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Respiratory Virus Vaccines Market Research Analysis
1. Introduction of the Global Respiratory Virus Vaccines Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Respiratory Virus Vaccines Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Respiratory Virus Vaccines Market, By Type
6. Global Respiratory Virus Vaccines Market, By Application
7. Global Respiratory Virus Vaccines Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Respiratory Virus Vaccines Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/